FDA extends priority review of oral MS drug Cladribine
FDA extends priority review of oral MS drug Cladribine
The U.S. drugs watchdog will take more time to decide over Merck KGaA's multiple sclerosis (MS) pill, the German company said on Friday, two months after drawing a rejection from European regulators.
The U.S. Food and Drug Administration (FDA) extended its review period for cladribine pills as a therapy for relapsing forms of (MS) by three months to Feb. 28, 2011, Merck said.
"The FDA extended the review period to provide additional time for a full review of additional information provided under the new drug application," the company added.... [Read More] - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1854 Views
-
Last post by frodo
-
- 0 Replies
- 1980 Views
-
Last post by NHE
-
- 0 Replies
- 1216 Views
-
Last post by frodo
-
- 1 Replies
- 1697 Views
-
Last post by frodo
-
- 0 Replies
- 1675 Views
-
Last post by frodo
-
- 0 Replies
- 1198 Views
-
Last post by NHE
-
- 0 Replies
- 982 Views
-
Last post by frodo
-
- 0 Replies
- 1061 Views
-
Last post by frodo
-
- 1 Replies
- 1398 Views
-
Last post by NHE